A
GLUE icon

AlphaQuest’s Monte Rosa Therapeutics GLUE Stock Holding History

AlphaQuest’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,322
Closed -$444K – 827
2025
Q4 		$444K Buy
28,322
+1,071
+4% +$14.4K 0.02% 914
2025
Q3 		$202K Hold
27,251
– – 0.01% 1402
2025
Q2 		$123K Hold
27,251
– – 0.01% 1365
2025
Q1 		$126K Sell
27,251
-67,382
-71% -$413K 0.01% 1203
2024
Q4 		$657K Buy
+94,633
New +$710K 0.09% 374

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

AlphaQuest's GLUE Position: Q1 2026 in Review

AlphaQuest sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 28,322 shares — an estimated $444K sold.

AlphaQuest first reported a position in GLUE in Q4 2024 and held it in 5 quarters. The position peaked at $657K in Q4 2024. 191 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • AlphaQuest reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 28,322 Monte Rosa Therapeutics shares in Q1 2026, an estimated $444K.
  • AlphaQuest first reported a position in Monte Rosa Therapeutics in Q4 2024 and held it in 5 quarters.
  • AlphaQuest's Monte Rosa Therapeutics position peaked at $657K in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.